Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 116

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 116
---
 hospital-acquired infections such as ventilator
acquired pneumonia, bloodstream infections, and neonatal sepsis. Further, this startup develops treatment options for multi-drug resistant
tuberculosis and cystic fibrosis. Their Toframicin agent is currently undergoing preclinical development and is already delivering in-vitro
results. The US-based startup Geom Therapeutics, in partnership with a Korean biotechnology company LegoChem Biosciences, provides GT-1,
a novel cephalosporin class antibiotic. GT-1, with the help of a siderophore receptor, binds with iron and takes a trojan horse approach
to attack the resistant bacteria. The Global Antibiotic Research & Development Partnership (GARDP) in collaboration with Innoviva
Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), recently announced that zoliflodacin, a clinically competitive
candidate antibiotic, met its primary endpoint in an global pivotal phase 3 clinical trial (for the treatment of gonorrhoea indication).
Study investigators found that oral zoliflodacin demonstrated statistical non-inferiority of microbiological cure at the urogenital site
when compared to treatment with intramuscular (IM) injection of ceftriaxone and oral azithromycin, a current global standard of care
regimen. In the study, zoliflodacin was found to be generally well tolerated and there were no serious adverse events or deaths recorded
in the trial.

<div align='center'>71</div>

In addition to traditional small molecule
antibiotics, there is significant research and development activity in the field of antibiotic combination therapies. These are compounds
that, when used in combination with existing antibiotics, can enhance their efficacy, expand their spectrum of activity, or overcome
resistance mechanisms.

VenatoRx Pharmaceuticals and Forge Therapeutics
are exploring beta-lactamase inhibitors and metalloenzyme inhibitors as potential combination therapys to restore the activity of beta-lactam
antibiotics against resistant strains.

Bacteriophage therapy represents another emerging
area of competition. This approach utilizes viruses that specifically target and kill bacteria, offering a highly selective alternative
to conventional antibiotics. Companies like Pherecydes Pharma and BiomX are at the forefront of developing phage-based therapies for indications
where antibiotic resistance is a significant concern, such as infections caused by MRSA and Pseudomonas aeruginosa.

Antimicrobial peptides (AMPs